The said certificate is valid for a period of 3 years and opens up the European and other markets for the company's products
Ryght AI tackles these hurdles with its AI Site Twin platform
If approved, CUTX-101 will be the first and only FDA approved treatment available for Menkes disease
The state-of-the-art facility is a 350-bedded, multi-specialty tertiary care hospital
The reform is set to modernise how medicines are developed, authorised, and made available across the EU
Alphyn is developing Zabalafin Hydrogel as the first therapy to simultaneously tackle the interconnected drivers of AD
Indoco received the Establishment Inspection Report from the USFDA for its API manufacturing facility
This is also an important milestone in our product strategy for our expansion into the larger Latin American market
The plant can reach an annual capacity of 300 crore tablets and 90 crore capsules
Subscribe To Our Newsletter & Stay Updated
